IDiyas

For the Inventor, By the Inventor

Yokohama, Japan

Yasuaki Ogawa

USPTO Granted Patents = 8

Average Co-Inventor Count = 7.7

ph-index = 2

Forward Citations = 14(Granted Patents)


Location History:

  • Yokohama, JA (1976 - 1978)
  • Yokohama, JP (1978 - 1981)

Company Filing History:

goldMedal8 out of 382 
 
Meiji Seika Kaisha, Ltd.
 patents

Years Active: 1976-1981

Loading Chart...
8 patents (USPTO):Explore Patents
1. 4283389 - Novel antibiotic, BN-183B substance (1981-08-11),
2. 4220639 - Antibiotics SF-2050 and SF-2050B substances and production and use (1980-09-02),
3. 4202886 - Antibiotic SF-1942 substance and process for production of the same (1980-05-13),
4. 4103083 - Novel antibiotics derivatives and process for preparing the same (1978-07-25),
5. 4076588 - Antibiotic SF-1623 substance and the production thereof (1978-02-28),
6. 4010155 - Antibiotic SF-1623 substance (1977-03-01),
7. 3975235 - Process for the production of cephamycin type antibiotic substances (1976-08-17),
8. 3974035 - Process for preparing a cephamycin type antibiotic substance (1976-08-10),

Title: Yasuaki Ogawa: Innovator in Antibiotic Development

Introduction

Yasuaki Ogawa is a prominent inventor based in Yokohama, Japan. He has made significant contributions to the field of antibiotic research, holding a total of 8 patents. His work focuses on developing novel antibiotics that combat various bacterial infections.

Latest Patents

Among his latest patents is the novel antibiotic designated BN-183B substance. This antibiotic is produced by cultivating a strain of the genus Pseudomonas and exhibits strong action against both Gram-positive and Gram-negative bacteria. Additionally, he has developed new antibiotics, SF-2050 substance and SF-2050B substance, which are produced by cultivating a microorganism, Streptomyces sp. SF-2050. These antibiotics can be isolated from the fermentation broth and are useful as antibacterial agents, demonstrating activity inhibitory to β-lactamase.

Career Highlights

Yasuaki Ogawa is associated with Meiji Seika Kaisha, Ltd., where he continues to innovate in the field of antibiotic development. His research has the potential to significantly impact the treatment of bacterial infections, addressing the growing concern of antibiotic resistance.

Collaborations

He has collaborated with notable coworkers, including Takashi Shomura and Shigeharu Inouye, contributing to the advancement of antibiotic research and development.

Conclusion

Yasuaki Ogawa's work in developing novel antibiotics positions him as a key figure in the fight against bacterial infections. His innovative contributions are vital in addressing public health challenges related to antibiotic resistance.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…